ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0452

Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Abstract Number: 1873

TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
Abstract Number: 2335

The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
Abstract Number: 2411

The 2019 EULAR/ACR and 2012 SLICC Classification Criteria for SLE Should Be Applied with Caution as Diagnostic Criteria
Abstract Number: 2630

The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
Abstract Number: 0434

The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
Abstract Number: 2383

The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
Abstract Number: 1761

The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Abstract Number: 0854

The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
Abstract Number: 2144

The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
Abstract Number: 1337

The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
Abstract Number: 1317

The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Abstract Number: 2678

The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
Abstract Number: 2515

The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
Abstract Number: 0171

The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].